{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:19:27Z","timestamp":1788459567163,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.amjcard.2019.11.014","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T02:15:48Z","timestamp":1574129748000},"page":"643-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5055-3226","authenticated-orcid":false,"given":"Mohammad Saud","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelmoniem","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2019.11.014_bib0001","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0002","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0003","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamacardio.2015.0356","article-title":"Treatment of heart failure with preserved ejection fraction: reflections on its treatment with an aldosterone antagonist","volume":"1","author":"Pfeffer","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0005","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0006","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ahj.2011.01.027","article-title":"Potential impact of optimal implementation of evidence-based heart failure therapies on mortality","volume":"161","author":"Fonarow","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0007","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jama.2009.1493","article-title":"Use of aldosterone antagonists in heart failure","volume":"302","author":"Albert","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002612","article-title":"Effectiveness and safety of aldosterone antagonist therapy use among older patients with reduced ejection fractionafter acute myocardial infarction","volume":"5","author":"Wang","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0009","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"Hernandez","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0010","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0011","unstructured":"Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-randomized Studies in Meta-Analysis. Ottawa, Ontario: The Ottawa Health Research Institute. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (April 03, 2019, date last accessed)."},{"key":"10.1016\/j.amjcard.2019.11.014_bib0012","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0013","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0014","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.amjcard.2014.03.062","article-title":"Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml\/min\/1.73 m(2.)","volume":"114","author":"Inampudi","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0016","first-page":"1097","article-title":"Spironolactone in acute heart failure patients with renal dysfunction and risk factors for diuretic resistance: from the ATHENA-HF trial","volume":"35","author":"Greene","year":"2019","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0017","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2015.01.014","article-title":"Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: data from the Korean Heart Failure Registry","volume":"169","author":"Oh","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0018","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000454933","article-title":"Spironolactone treatment and effect on survival in chronic heart failure patients with reduced renal function: a propensity-matched study","volume":"7","author":"Stubnova","year":"2017","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0019","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11906-012-0297-0","article-title":"The ubiquitous mineralocorticoid receptor: clinical implications","volume":"14","author":"Hawkins","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0021","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0022","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0023","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0024","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2015.05.001","article-title":"US renal data system 2014 annual data report: epidemiology of kidney disease in the United States","volume":"66","author":"Saran","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0025","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0026","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2013.09.057","article-title":"Mineralocorticoid receptor antagonists in patients with end-stage renal disease on chronic hemodialysis","volume":"63","author":"Pitt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0027","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.amjcard.2019.11.014_bib0028","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2016.04.011","article-title":"The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis","volume":"68","author":"Quach","year":"2016","journal-title":"Am J Kidney Dis"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919313086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914919313086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:32:48Z","timestamp":1757572368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914919313086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0002914919313086"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.11.014","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737121012.793571782","asserted-by":"object"}]},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2019.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}